Updates

Per-node confidence is computed live from the database. Below is the update history.

Node status

638 nodes · T4 638

Confidence is scored on two axes — Proof (P): sources, filings, cross-verification, securities research; Ripple (R): revenue, cost, investment, graph links. 6 points each.

Update history

• Oct 15, 2026Re-researched and re-verified the Hitachi full nodeDoneCross-checked record FY2026 Q1 results with Korean and English sources and updated three revenue edges. Corrected the Hitachi Construction Machinery stake from 25.42% to 18.36% and mirrored the loss of equity-method status both ways. Attributed the Whitehaven equipment relationship to HCM revenue and re-verified that existing hub.
• Oct 15, 2026Re-researched and reverified the Cummins nodeDoneCross-checked Q2 2026 Power Systems sales of $2.3 billion (+19%) using the SEC filing and Korean broker research. Added Whitehaven Coal as a direct customer edge, reverified the reciprocal PACCAR relationship with the 2025 10-K, and kept exact-match closure and one-way links at zero.
• Oct 15, 2026Expanded Hitachi Construction Machinery into a full nodeDoneBuilt a 2-revenue, 2-cost and 2-investor structure from the Q1 2026 filing and Korean/English cross-checks, closing reciprocal links to Cummins, Hitachi and ITOCHU. Re-verified ITOCHU ownership at 33.4%.
• Oct 14, 2026Federal Realty expanded to T4 with TJX re-verificationDoneVerified $1.245 billion of 2025 rental income, $24.116 million of annualized base rent from largest tenant TJX and $286.2 million drawn on the Wells Fargo-administered revolver using the 2025 10-K and Q2 2026 disclosures. Cross-verified the Annapolis and Village Pointe acquisitions in Korean and English and refreshed the reciprocal TJX relationship.
• Oct 14, 2026Olympus T4 node expansion with DuPont and Canon re-verificationDoneVerified FY2027 Q1 revenue of JPY240.4 billion, Gastrointestinal Solutions revenue of JPY168.4 billion, Surgical & Interventional Solutions revenue of JPY71.9 billion and cost of sales of JPY83.6 billion. Cross-verified DuPont Tyvek and Canon Medical supply relationships in Korean and English, added the $270 million BioProtect acquisition, and closed reciprocal DuPont and Canon links.
• Oct 14, 2026DuPont full-node expansion and Qnity re-verificationDoneReframed DuPont from its FY2025 10-K as a healthcare, water and industrial-technology company and built a 3-revenue, 3-cost, 2-investment structure. Added reciprocal Olympus, Qnity and IFF links with KO+EN cross-verification; re-verified Qnity at H1 2026 sales of $2.744 billion (+20%) from its Q2 filing.
• Oct 13, 2026Ball expanded: beverage-can customer concentration and aluminum cost chainDoneVerified $13.161 billion of 2025 sales, 40% concentration across the top three disclosed customers, and H1 2026 sales of $7.600 billion against $6.257 billion of cost of sales from SEC filings. Added the Novelis long-term can-sheet contract, the 80% Benepack acquisition and reciprocal Monster/Constellation links, while reverifying the Monster hub with Korean-language research.
• Oct 13, 2026Blackstone reverified: Q2 2026 AUM and the Leqvio royalty chainDoneUpdated AUM to $1.3463 trillion, quarterly FRE to $1.78 billion and perpetual-capital AUM to $555.6 billion from the Q2 2026 SEC filing. Alnylam's 10-Q and Novartis product-sales disclosure reverified Blackstone's 50% Leqvio royalty and 75% commercial-milestone interests against $1.198 billion of 2025 Leqvio sales on both sides of the relationship. The existing Alnylam hub was refreshed, with no new edges and zero exact-match or one-way-link gaps retained.
• Oct 12, 2026Alnylam Pharmaceuticals expanded to a T4 reference nodeDoneQuantified product, Roche and Regeneron revenue, Agilent sole-source API supply, Sanofi royalties and Blackstone’s $1 billion financing structure using the FY2025 10-K and Q2 2026 disclosures. Closed reciprocal links with Regeneron, Agilent and Blackstone and reverified Regeneron against its Q2 2026 10-Q.
• Oct 12, 2026Coca-Cola Europacific Partners full-node expansionDoneExpanded the baseline node to a T4-target structure using FY2025 revenue of €20.9 billion, €4.5 billion of net Coca-Cola-related cost-of-sales transactions, and Coca-Cola's 17.59% stake. Closed reciprocal links with Monster, ADP, Dover and Coca-Cola, and reverified Coca-Cola against its 2025 10-K and Q2 2026 results.
• Oct 12, 2026American Express node expansionDonePromoted the baseline into a researched finance node. Cross-checked the 2025 10-K and Q2 2026 10-Q against Korean Credit Card Research Institute research; connected merchant and Card Member revenue, Delta, Hilton and Marriott partner payments, Berkshire's 22.5% stake and the GBTG investment. Berkshire was re-verified against its latest 10-Q.
• Oct 11, 2026Satellogic upgraded T3 to T4: reciprocal Palantir link, Officina investment and Q2 2026 resultsDoneCross-verified Satellogic's Palantir Foundry and Edge AI cost link and Palantir's reciprocal revenue link with Korean and English sources. Separated the 5% Officina Stellare stake into the investment structure, and reflected Q2 2026 revenue of $15.9M (+259%), first positive operating income, and defense contracts above $18M and at $12M. Re-verified hub Palantir against its Q2 10-Q at $1.935B revenue (+93%).
• Oct 11, 2026Hyundai Motor H1 2026 re-verification: Hyundai Transys supply and ownership linksDoneCross-verified Hyundai Transys' seat and next-generation hybrid-powertrain supply relationship and Hyundai Motor's 41.13% stake using Hyundai Motor's H1 2026 filing and Hyundai Transys' English sustainability report. Refreshed FY2025 and H1 2026 results, the 25.35% Hyundai Wia stake, and the chain analysis note. Kept Hyundai Transys promotion next in the queue.
• Oct 11, 2026Hyundai Wia promoted to a T4 reference nodeDoneQuantified Hyundai Motor and Kia sales, Hyundai Transys and Wia Magna purchases, and Hyundai Motor's 25.35% stake from the H1 2026 filing. Cross-verified K2/K9 artillery supply with Korean and English first-party sources plus Samsung Securities research, and completed reciprocal links to four nodes.
• Oct 10, 2026Legrand upgraded T3 to T4: direct Microsoft and Equinix links, CRS acquisition, Microsoft FY2026 re-verificationDoneLegrand's CDP disclosure confirms EUR 127.1M of Microsoft revenue through Starline and EUR 13.6M of Equinix revenue through Minkels and Legrand North America, closing both reciprocal links. Added the CRS acquisition (about EUR 30M acquired annual revenue), sell-side consensus, and the 2026 Capital Markets Day outlook of 32% data-center exposure and more than EUR 3B in sales. Re-verified Microsoft with its FY2026 10-K: $331.8B revenue and $115.9B of property-and-equipment additions.
• Oct 10, 2026Hyundai Rotem value-chain upgrade to T4DoneUpdated the business mix with first-half 2026 IR, cross-verified Hyundai Motor's 33.8% stake, Hyundai Wia's K2 main-gun supply, and Samsung Securities research with Korean and English sources, and completed reciprocal investment links plus Hyundai Motor re-verification.
• Oct 10, 2026Danaher upgraded T3 to T4: Moderna link via Aldevron plasmid DNA (both ways), Abcam acquisition as investment structure, Moderna re-verified on H1 2026DoneLinked Danaher's Aldevron supplying plasmid DNA for Moderna's mRNA vaccines (agreement expanded May 2021) both ways, as a Danaher revenue edge and a Moderna cost edge (Business Wire, BioSpectator, Danaher 2021 10-K). Added the December 2023 Abcam acquisition (about $5.6B cash, about £362M 2022 revenue, about $3.9B goodwill) as investment structure from the 2023 10-K, IR release and BioSpectator. Re-verified hub: Moderna Q2 2026 10-Q (H1 revenue $534M, Q2 operating loss $815M, Merck intismeran 50:50 cost and profit split reconfirmed). Broker research is still missing. The article and house overview were skipped this run for time.
• Oct 10, 2026Sidus Space strengthened: T3 to T4 with disclosed customer concentration and a Teledyne linkDoneFilled customer shares from the customer-concentration tables in the 10-K and Q2 10-Q: in 2025 Craig Technologies (CEO-owned affiliate) 47% and Bechtel 14%; in H1 2026 Teledyne Marine 20%, Craig 17% and Lonestar 14%. Linked Teledyne Marine component supply (2019 supply agreement) both ways with the Teledyne node, and added CTC's Class B holding from the DEF 14A proxy as investment structure. Reflected the $146.2M April and May offerings and $166.5M of end-June cash. Re-verified hub: Teledyne Q2 2026 results (sales $1.66B, up 9.8%, a quarterly record). Broker research and Korean-language media coverage are still absent.
• Oct 10, 2026AbCellera upgraded T3 to T4: direct Lilly and AbbVie links (both ways), Jazz $56M upfront, Bruker $36M patent settlement, JVs and government funding; AbbVie re-verified on H1 2026DoneUsed the FY2025 10-K, Q2 2026 10-Q and the ABCL635 Phase 2 8-K to confirm $75.1M revenue (fixing the old $33.7M figure), $12.4M in H1 2026 and $540M cash. Linked the Lilly and AbbVie revenue edges to their nodes and added the paying-side pairs. New edges for Jazz, Bruker, the Dayhu/Beedie JVs and Canada/BC funding, plus an analyst-consensus source. AbbVie refreshed with Skyrizi and Rinvoq figures from its Q2 2026 10-Q.
• Oct 9, 2026Ecopro HN deepened: KRW 93.6bn Micron Singapore and KRW 40.7bn Idaho (Hoffman) orders; Micron FY2026 re-verifiedDoneFilled revenue (Micron, Hoffman, Samsung E&A, BHI, EcoPro BM, EcoPro Materials) and cost edges (raw materials, Ecopro, Wangsan Electric) with amounts from the DART H1 2026 report and five supply-contract filings, closing reciprocal pairs; cross-checked with English media (Digital Today). Micron overview refreshed from its FY2026 10-K ($133.2B revenue, +256%, no 10%+ customer).